Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone… Read More
ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in… Read More
HYDERABAD, IN & VANCOUVER, BC – Mapmygenome, an AI-driven leader in genomics and personalized health, announced the strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition… Read More
For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their home, thanks to an innovative research initiative by Horizon Health Network… Read More
WELL Health is pleased to report that HEALWELL’s wholly owned subsidiary Intrahealth, non-wholly owned subsidiary Pentavere along with WELLSTAR’s subsidiary OceanMD have been selected by Canada Health Infoway as recipients… Read More
